Euroopa Liit -
eesti -
EMA (European Medicines Agency)
lutetium (177lu) chloride billev (previously illuzyce)
billev pharma aps - lutetium (177lu) chloride - radionukliidi pildistamine - terapeutilised radiofarmatseutilised ühendid - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.
Eesti -
eesti -
Ravimiamet
vedida infusioonilahuse pulber
medochemie limited - vorikonasool - infusioonilahuse pulber - 200mg 1tk
Eesti -
eesti -
Ravimiamet
voriconazole sandoz õhukese polümeerikattega tablett
sandoz pharmaceuticals d.d. - vorikonasool - õhukese polümeerikattega tablett - 200mg 30tk; 200mg 1000tk; 200mg 10tk; 200mg 14tk; 200mg 56tk; 200mg 20tk; 200mg 50tk; 200mg 98tk; 200mg 60tk
Eesti -
eesti -
Ravimiamet
voriconazole sandoz õhukese polümeerikattega tablett
sandoz pharmaceuticals d.d. - vorikonasool - õhukese polümeerikattega tablett - 50mg 56tk; 50mg 500tk; 50mg 28tk; 50mg 98tk; 50mg 2tk; 50mg 14tk; 50mg 100tk; 50mg 1000tk; 50mg 10tk
Eesti -
eesti -
Ravimiamet
ezoleta tablett
first pharma oÜ - esetimiib - tablett - 10mg 56tk; 10mg 30tk; 10mg 100tk; 10mg 98tk; 10mg 50tk; 10mg 14tk; 10mg 60tk; 10mg 90tk
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
celsunax
pinax pharma gmbh - ioflupane (123i) - radionuclide imaging; dementia; movement disorders - diagnostilised radiofarmatseutilised ühendid - see ravim on mõeldud ainult diagnostiliseks kasutamiseks. celsunax is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. celsunax is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy. täiskasvanud patsientidel, et aidata eristada arvatav dementsus koos lewy kehad alzheimeri tõbi. celsunax is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.